Feedback / Questions
camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics
ADCT-901 - Overland ADCT BioPharma
Zynlonta (loncastuximab tesirine) - Overland ADCT BioPharma, Mitsubishi Tanabe, SOBI
Keytruda (pembrolizumab) - Merck (MSD)
https://www.businesswire.com/news/home/20220809005173/en/ADC-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Updates
Aug 9, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next